MeSH D014890 - granulomatosis with polyangiitis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Cyclophosphamide | Neosar | 1993-04-29 | |||
| Dr Reddys Laboratories | Cyclophosphamide | Cyclophosphamide | 2036-02-15 | 2020-07-30 | ||
| Roche | Rituximab | MabThera | 1998-06-02 | |||
| Cipla | Cyclophosphamide | Cyclophosphamide | 2019-01-18 | |||
| Sandoz | Rituximab | Rixathon | 2017-06-15 | |||
| Rituximab | Riximyo | 2017-06-15 | ||||
| Cyclophosphamide | Cyclophosphamide | 2023-09-12 | ||||
| Pfizer | Rituximab | Ruxience | 2019-07-23 | $390 M | Y2023 | |
| Alembic Pharmaceuticals | Cyclophosphamide | Cyclophosphamide | 2022-11-10 | |||
| Amneal Pharmaceuticals | Cyclophosphamide | Cyclophosphamide | 2018-05-25 | |||
| Biogen | Rituximab | Rituxan | 2002-02-19 | |||
| ANI Pharmaceuticals | Cyclophosphamide | Cyclophosphamide | 2018-03-19 |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
100%7/7
Phase 2
70%16/23
Phase 3
57%16/28
Approved: 4Overall Success rate: 40%
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use